Skip to main content
padlock icon - secure page this page is secure

C. elegans: An All in One Model for Antimicrobial Drug Discovery

Buy Article:

$68.00 + tax (Refund Policy)

One approach to identify new drugs with antimicrobial activities is to screen large libraries of molecules directly for their capacity to block the growth of bacterial or fungal monocultures. A more relevant way to assess both a product's efficacy and its potential cytotoxicity is undoubtedly to use an in vivo infection system. Testing banks containing thousands of natural or chemically synthesized molecules with rodents is generally neither desirable nor feasible. Therefore, invertebrate model organisms could represent a valuable alternative. In this review, we present the worm C. elegans as a suitable host model for the evaluation and characterization of drug effects in a pathogenesis context. This simple organism has been of great value in many fields of biology and is currently intensely used in studies of hostpathogen interactions. Infection of C. elegans induces a number of defense mechanisms, some of which are similar to those seen in mammalian innate immunity. Further, it has been demonstrated that several microbial virulence mechanisms required for full pathogenicity in mammals are also necessary for infection in nematodes. Based on these facts, a number of innovative antimicrobial drug screens have been carried out successfully and the development of new tools to monitor the interaction between worm and microbes in vivo opens promising perspectives.





No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Antimicrobial; C. elegans; drug discovery; high-throughput; host sress response; infection; microbes; pathogen; screen; virulence

Document Type: Research Article

Publication date: June 1, 2011

More about this publication?
  • Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more